Toll Free: 1-888-928-9744

Intravenous Solutions

Published: Apr, 2015 | Pages: 327 | Publisher: RESEARCH IMPACT TECHNOLOGIES
Industry: Biotechnology | Report Format: Electronic (PDF)

This market insight report on IV (Intravenous) Solutions is analyzed by Type and Nutrients for each of the geographic regions-North America, Europe, Asia-Pacific and Rest of World. The global IV Solutions market segments includes by Type- Partial Parenteral Nutrition (PPN) & Total Parenteral Nutrition (TPN); by Nutrients-Carbohydrates, Salt and Electrolytes, Minerals and Vitamins and Amino Acids. Estimations and predictions for the total global IV solutions market are given by geographic regions. Business profiles of 16 major companies are discussed in the report. The report covers more than 50 companies that are engaged in IV Solutions and related products. Major Contract Research Organizations serving IV Solution market are also covered in the Corporate Directory section of this report. Information related to product developments, partnerships, collaborations, and mergers and acquisitions is also included in the report. A total of 110 exclusive graphically represented exhibits complement the text.
 Table of Content

1. SCOPE AND METHODOLOGY	1
2. REPORT SYNOPSIS	3
2.1 Introduction	3
History	3
Definitions	4
Intravenous	4
Intravenous Infusions	4
Parenteral	4
Enteral	4
Home Parenteral Nutrition (HPN)	4
Partial Parenteral Nutrition (PPN)	5
Total Parenteral Nutrition (TPN)	5
Benefits	5
Hazards of Intravenous Feeding	5
2.2 Segmentation of Intravenous Solutions	5
Exhibit 1. Segmentation of Intravenous Solutions Market by Type and Nutrients	5
2.2 Intravenous Solutions - Global Market Analysis	6
Exhibit 2. Intravenous Solutions - Global Historic Market (2000-2010) in US$ Billion	6
Exhibit 3. Intravenous Solutions - Global Market Estimations & Predictions (2011 - 2020) in US$ Billion	7
Exhibit 4. List of Major Global Companies in Intravenous Solutions Market	7
3. MARKET DYNAMICS	9
3.1 Market Overview	9
Economic Profile	9
Market Growth Factors	9
3.2 Global Intravenous Solutions Market	11
Exhibit 5. Intravenous Solutions - Global Historic Market (2000-2010) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	11
Exhibit 6. Intravenous Solutions - Global Market Shares (2005 & 2010) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	12
Exhibit 7. Intravenous Solutions - Global Market Estimations & Predictions (2011 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	13
Exhibit 8. Intravenous Solutions - Global Market Shares (2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	14
3.3 North America Intravenous Solutions Market	15
Exhibit 9. Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for United States and Canada in US$ Million	15
Exhibit 10. Intravenous Solutions – North American Market Shares (2010, 2015 & 2020) by Country for United States and Canada	16
3.3 (I) US Intravenous Solutions Market	16
3.3 (II) Canadian Intravenous Solutions Market	16
Exhibit 11. List of Major North American Intravenous Solutions Companies	16
3.4 European Intravenous Solutions Market	17
Exhibit 12. Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe in US$ Million	17
Exhibit 13. Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe	18
3.4 (I) German Intravenous Solutions Market	18
3.4 (II) French Intravenous Solutions Market	18
3.4 (III) UK Intravenous Solutions Market	18
3.4 (IV) Swiss Intravenous Solutions Market	18
3.4 (V) Russian Intravenous Solutions Market	19
Exhibit 14. List of Major European Intravenous Solutions Companies	19
3.5 Asia-Pacific Intravenous Solutions Market	20
Exhibit 15. Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million	20
Exhibit 16. Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	21
3.5 (I) Japanese Intravenous Solutions Market	21
3.5 (II) Chinese Intravenous Solutions Market	21
3.5 (III) Indian Intravenous Solutions Market	21
3.5 (IV) Australian Intravenous Solutions Market	21
3.5 (V) South Korean Intravenous Solutions Market	21
Exhibit 17. List of Major Asia-Pacific Intravenous Solutions Companies	22
3.6 Rest of World Intravenous Solutions Market	23
Exhibit 18. Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Brazil, Israel, South African and Rest of World in US$ Million	23
Exhibit 19. Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Brazil, Israel, South African and Rest of World	24
3.6 (I) Brazilian Intravenous Solutions Market	24
3.6 (II) Israeli Intravenous Solutions Market	24
3.6 (III) South African Intravenous Solutions Market	24
3.7 Major Global Players in Intravenous Solutions Market	25
Ajinomoto Co., Inc. (Japan)	25
B. Braun Melsungen AG (Germany)	26
Baxter International, Inc. (USA)	28
Baxter (India) Pvt. Ltd. (India)	29
Claris Otsuka Private Ltd. (India)	30
Fresenius Kabi AG (Germany)	32
Hospira, Inc. (USA)	34
Kyowa Hakko Bio Co., Ltd. (Japan)	37
Laboratorios Grifols SA (Spain)	38
Liqvor Pharmaceuticals (Armenia)	40
Amanta Healthcare Ltd. (India)	43
Otsuka Pharmaceutical Co., Ltd. (Japan)	46
Sichuan Kelun Pharmaceutical Co., Ltd. (China)	46
Sino-Swed Pharmaceutical Corp., Ltd. (China)	47
Terumo Corporation (Japan)	48
3.8 Competition Analysis	50
Exhibit 20. Clinical Nutrition Market: 2012 Percentage Market Share of Major Companies	50
Exhibit 21. Intravenous Solution Products Market: 2013 Percentage Market Share of Major Companies	51
Exhibit 22. Companies in Intravenous Solutions Market – Annual Sales for 2006 through 2010 in US$ Million	51
Exhibit 23. Companies in Intravenous Solutions Market – Production Volume and Capacity  in Unit/Tonnes/Liters	52
Exhibit 24. Solutions – Competitor Price Comparison	52
3.9 Major Activities in Intravenous Solutions Market	53
Baxter Plans to Build a New Intravenous Admixing Facility in Canada	53
Fresenius Kabi Launches Kabiven® in the US	53
Mallinckrodt Acquires Cadence Pharmaceuticals for US$ 1.4 Billion	54
Cardiome Acquires Correvio LLC	54
Grifols Enters into Agreement with Cumberland Pharmaceuticals to Market Ibuprofen for Intravenous Infusion	54
FDA Approves New Large-Volume Intravenous Containers of B. Braun Medical	55
Fresenius Kabi Forms JV for I.V. Generics	55
Sandoz Launches Authorized Generic Version of Argatroban Injection	55
BPC’s BIVIGAM™, a New Intravenous Immune Globulin Gains US FDA Approval	55
Hospira Recalls Electrolyte Solution	56
Otsuka, Mitsui and Claris Establish an IV Solutions Joint Venture Business in India	56
Kyowa Hakko Kirin Introduces the new NESP® INJECTION PLASTIC SYRINGE with Unified Injection Volume	56
Taiho Pharmaceutical Releases 5-HT3 Receptor Antagonist Aloxi® I.V. Infusion bag 0.75mg	57
Merck to Give Back Vernakalant’s Worldwide Marketing and Development Rights to Cardiome	57
Baxter Healthcare to Withdraw Automix Automated Nutrition Compounder Systems	57
Rienso® (ferumoxytol) Attains Marketing Authorization by EC for Iron Deficiency Anaemia Treatment in Adult Chronic Kidney Disease Patients	57
MTPC’s Label Extension for Remicade Facilitate in Shorter Infusion Time	58
Shionogi Gains Pediatric Use and Additional Indication Approvals for Purulent Meningities of Carbapenem-Type Antibiotic in Japan	58
Intravenous Solution Manufacturing Plant establishment in Sri Lanka	58
Hospira Introduces Imipenem-Cilastatin for injection, I.V in the US	59
Shionogi Introduces Carbapenem-type Antibiotic, Finibax® 0.5 g for Intravenous Drip Infusion	59
Baxter Acquires Baxa Corporation	59
Baxter Launches NUMETA, as the first Triple-Chamber IV Nutrition System for Premature Newborns and Children in Europe	60
FDA Grants 510(K) clearance to Introcan Safety® 3 Closed IV Catheter from B. Braun Medical	60
BD Introduces New Generation Short Peripheral IV Catheter	61
Mitisubishi Tanable Introduces Simponi Subcutaneous Injection 50mg Syringe	61
Benesis’ Venoglobulin IH 5% for Intravenous Injection Receives Approval for Additional Indication	61
Mitsubishi Tanabe Receives Approval for Partial Change in Dosage & Usage of Remicade for I.V. Infusion 100	62
OLIMEL, First Triple-Chamber Bag for Nutrition, Launched in Canada by Baxter	62
Daiichi Sankyo Launches Cravit® Intravenous Injections	63
Cadence Pharmaceuticals Launches OFIRMEV™ (acetaminophen) Injection, the First and Solitary Intravenous Formulation of Acetaminophen in the US	63
AmeriCares Enters into a Partnership Agreement with Baxter to offer Additional Lifesaving Intravenous Solutions to Haiti	63
Marck Biosciences Acquires Assets of Goa-based Ravish Infusion	64
Fresenius Medical Care and Galenica Establish Renal Pharmaceutical Company	64
Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV	64
Grifols Announces the Launch of FLEBOGAMMA® 10% DIF IVIG	65
Hospira Enters into New Contracts with Novation for Infusion Pumps, Solutions and Equipment	65
Venoglobulin®-IH 5% IV Approved for Additional Indications of Dermatomyositis and Polymyositis	66
GlaxoSmithKline and Genmab Alter Ofatumumab Development Program in Autoimmune Indications	66
BRINAVESS™ (vernakalant) IV for Infusion Granted Marketing Approval in the EU for Rapid Conversion of Recent Onset Atrial Fibrillation	66
Taiho Pharmaceutical to Launches Antineoplastic ABRAXANE®	66
Paracetamol IV in Plastic Pack	67
EMA Accepts MMA for FERAHEME® of AMAG Pharmaceuticals and Takeda; Global Registration Program for FERAHEME® to Treat Iron Deficiency Anemia Initiated	67
Grifols Acquires Talecris	67
CareFusion Concludes the Acquisition of Medegen	68
BioScrip Acquires Critical Homecare Solutions	68
RADICUT® BAG for IV Infusion 30mg, a New Dosage form of Cerebral Neuroprotectant RADICUT® injection 30 mg, Approved	68
Mitsubishi Tanabe Pharma Obtains Approval for New Indication of Psoriasis	69
Hospira Launches Environmental Friendly IV Containers	69
Evolva SA Completes Merger with Arpida Ltd	70
Claris Introduces Anti-infective Injectable Unit	70
Pfizer Completes Acquisition of Wyeth	70
Celldex Therapeutics Completes Acquisition of CuraGen Corporation	70
HYLENEX Commercially Launched by Baxter	71
Hospira Enters into New Agreements with MedAssets for IV Solutions, Renews Infusion Devices Agreement	71
Marck Biosciences Enters Singapore and Malaysia	71
Baxter and SIGMA in Exclusive Distribution Agreement for Infusion Pumps	72
Talecris Biotherapeutics Launches Gamunex Connexions Certificate Program	72
Gamunex® of Talecris Biotherapeutics Approved by the USFDA as Treatment for Neurological Disorder CIDP	73
Arpida Files New Drug Submission for Intravenous Iclaprim in Canada	73
Fresenius Medical Care Closes US License Agreement for Intravenous Iron Products	73
Antimicrobial IV Technology of Baxter Demonstrates Capability to Eliminate Six Pathogens Inclusive of MRSA and VRE	74
Hospira Enters into New Contracts with Premier Purchasing Partners for Infusion Devices, Solutions and Equipments	74
Arpida Files Marketing Authorization Application in Europe for Intravenous Iclaprim	75
Fresenius Medical Care Enters into Agreements for Intravenous Iron Products	75
Otsuka Pharmaceutical and PDL BioPharma Conclude Sale of IV Busulfex	75
Fresenius Kabi Expands Infusion Therapy Business in Latin America	75
Otsuka to Acquire Busulfex® IV from PDL BioPharma	76
Hospira Obtains Marketing Authorization in the EU for Retacrit™	76
Voluven - Product for Prevention and Treatment of Severe Blood Volume Loss following Surgery – Approved by the FDA	76
New Safety Packaging Introduced by Baxter Healthcare for High Alert Drugs	76
Transition to NextGen IV Immunoglobulin- Flebogamma® DIF - Concluded in record time in the US by Grifols	77
Kyowa Hakko and Kirin Groups Formalize Strategic Alliance Agreement	77
Baxter in Joint Venture with Guangzhou Baiyunshan for Parenteral Nutritional Products in China	77
EMEA Authorizes NextGen IVIG Distribution in European Union	78
Kyowa Hakko Increases Amino Acid Prices in Europe	78
Shanghai Century Acquisition Corporation Acquires the Shares of Sichuan Kelun Pharmaceutical Co., Ltd	79
Advanced NutriSolutions Acquires Select Supplements from Kyowa Hakko	79
Mayne Pharma Acquisition Process Completed by Hospira	79
FDA issues Marketing License to Grifols for NextGen Intravenous Immunoglobulin (IVIG) in the US	79
Kyowa Hakko Releases White Paper Kit Attributed to Amino Acids and Related Compounds	79
Symbiq™ - The Next-Gen Infusion System from Hospira	80
Health Alliance of Greater Cincinnati to Replace its Entire Fleet of IV Pumps Across Seven Hospitals	80
Amigrand Intravenous Infusion Launched Jointly by Tanabe Seiyaku and Terumo	80
Systemic Fungal Infection Therapy AmBisome® 50 mg for Intravenous Drip Infusion - Launched	81
Kyowa Hakko Launches Lumistor™	81
The First Significantly Advanced Flexible IV Container in 3 decades	81
A New Line of Intravenous Solutions – AVIVA from Baxter	82
Cadence Pharmaceuticals Acquires Rights to IV APAP	82
BioScrip Inc. Launches Specialty Infusion Operations on Western Coast by Acquiring Intravenous Therapy Services	82
Boniva® - The First Intravenous Medication to treat Postmenopausal Osteoporosis, Approved by the FDA	82
Ajinomoto Acquires Amoy Food Group from Groupe Danone	83
FLEXBUMIN- the Flexible Container Packaged Albumin Solution from Baxter, Approved	83
3.10 Analysis by Type	84
Exhibit 25. Intravenous Solutions by Type - Global Historic Market (2000-2010) for PPN and TPN in US$ Million	84
Exhibit 26. Intravenous Solutions by Type - Global Market Shares (2005 & 2010) for PPN and TPN	85
Exhibit 27. Intravenous Solutions by Type - Global Market Estimations & Predictions (2011 - 2020) for PPN and TPN in US$ Million	86
Exhibit 28. Intravenous Solutions by Type - Global Market Shares (2015 & 2020) for PPN and TPN	87
3.10.1 Partial Parenteral Nutrition	88
3.10.1.1 Global Market for Partial Parenteral Nutrition	88
Exhibit 29. Partial Parenteral Nutrition - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	89
Exhibit 30. Partial Parenteral Nutrition - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	90
3.10.1.2 North America Market for Partial Parenteral Nutrition	91
Exhibit 31. Partial Parenteral Nutrition - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million	91
Exhibit 32. Partial Parenteral Nutrition - North American Market Shares (2010, 2015 & 2020) by Country US and Canada	92
3.10.1.2 (I) US Market for Partial Parenteral Nutrition	92
3.10.1.2 (II) Canadian Market for Partial Parenteral Nutrition	92
3.10.1.3 European Market for Partial Parenteral Nutrition	93
Exhibit 33. Partial Parenteral Nutrition - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million	93
Exhibit 34. Partial Parenteral Nutrition - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe	94
3.10.1.3 (I) German Market for Partial Parenteral Nutrition	94
3.10.1.3 (II) French Market for Partial Parenteral Nutrition	94
3.10.1.3 (III) UK Market for Partial Parenteral Nutrition	94
3.10.1.3 (IV) Swiss Market for Partial Parenteral Nutrition	94
3.10.1.3 (V) Russian Market for Partial Parenteral Nutrition	94
3.10.1.4 Asia-Pacific Market for Partial Parenteral Nutrition	95
Exhibit 35. Partial Parenteral Nutrition - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million	95
Exhibit 36. Partial Parenteral Nutrition - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	96
3.10.1.4 (I) Japanese Market for Partial Parenteral Nutrition	96
3.10.1.4 (II) Chinese Market for Partial Parenteral Nutrition	96
3.10.1.4 (III) Indian Market for Partial Parenteral Nutrition	96
3.10.1.4 (IV) Australian Market for Partial Parenteral Nutrition	96
3.10.1.4 (V) South Korean Market for Partial Parenteral Nutrition	96
3.10.1.5 Rest of World Market for Partial Parenteral Nutrition	97
Exhibit 37. Partial Parenteral Nutrition - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million	97
Exhibit 38. Partial Parenteral Nutrition - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries	98
3.10.1.5 (II) Brazilian Market for Partial Parenteral Nutrition	98
3.10.1.5 (I) Israeli Market for Partial Parenteral Nutrition	98
3.10.1.5 (III) South African Market for Partial Parenteral Nutrition	98
3.10.2 Total Parenteral Nutrition	99
3.10.2.1 Global Market for Total Parenteral Nutrition	99
Exhibit 39. Total Parenteral Nutrition - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	99
Exhibit 40. Total Parenteral Nutrition - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	100
3.10.2.2 North American Market for Total Parenteral Nutrition	101
Exhibit 41. Total Parenteral Nutrition - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million	101
Exhibit 42. Total Parenteral Nutrition - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada	102
3.10.2.2 (I) US Market for Total Parenteral Nutrition	102
3.10.2.2 (II) Canadian Market for Total Parenteral Nutrition	102
3.10.2.3 European Market for Total Parenteral Nutrition	103
Exhibit 43. Total Parenteral Nutrition - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million	103
Exhibit 44. Total Parenteral Nutrition - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe	104
3.10.2.3 (I) German Market for Total Parenteral Nutrition	104
3.10.2.3 (II) French Market for Total Parenteral Nutrition	104
3.10.2.3 (III) UK Market for Total Parenteral Nutrition	104
3.10.2.3 (IV) Swiss Market for Total Parenteral Nutrition	104
3.10.2.3 (V) Russian Market for Total Parenteral Nutrition	104
3.10.2.4 Asia-Pacific Market for Total Parenteral Nutrition	105
Exhibit 45. Total Parenteral Nutrition - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million	105
Exhibit 46. Total Parenteral Nutrition - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	106
3.10.2.4 (I) Japanese Market for Total Parenteral Nutrition	106
3.10.2.4 (II) Chinese Market for Total Parenteral Nutrition	106
3.10.2.4 (III) Indian Market for Total Parenteral Nutrition	106
3.10.2.4 (IV) Australian Market for Total Parenteral Nutrition	106
3.10.2.4 (V) South Korean Market for Total Parenteral Nutrition	106
3.10.2.5 Rest of World Market for Total Parenteral Nutrition	107
Exhibit 47. Total Parenteral Nutrition - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million	107
Exhibit 48. Total Parenteral Nutrition - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries	108
3.10.2.5 (II) Brazilian Market for Total Parenteral Nutrition	108
3.10.2.5 (I) Israeli Market for Total Parenteral Nutrition	108
3.10.2.5 (III) South African Market for Total Parenteral Nutrition	108
3.11 Analysis by Nutrients	109
Exhibit 49. Intravenous Solutions by Nutrients - Global Historic Market (2000-2010) for Carbohydrates, Salt & Electrolytes, Minerals & Vitamins, Amino Acids and Other in US$ Million	109
Exhibit 50. Intravenous Solutions by Nutrients - Global Market Shares (2005 & 2010) for Carbohydrates, Salt & Electrolytes, Minerals & Vitamins, Amino Acids and Other	110
Exhibit 51. Intravenous Solutions by Nutrients - Global Market Estimations & Predictions (2011 - 2020) for Carbohydrates, Salt & Electrolytes, Minerals & Vitamins, Amino-Acids and Other in US$ Million	111
Exhibit 52. Intravenous Solutions by Nutrients - Global Market Shares (2015 & 2020) for Carbohydrates, Salt & Electrolytes, Minerals & Vitamins, Amino-Acids and Other	112
3.11.1 Carbohydrates	113
3.11.1.1 Global Carbohydrate based Intravenous Solutions Market	113
Exhibit 53. Carbohydrate based Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	113
Exhibit 54. Carbohydrate based Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific, Japan and Rest of World	114
3.11.1.2 North American Carbohydrate based Intravenous Solutions Market	115
Exhibit 55. Carbohydrate based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million	115
Exhibit 56. Carbohydrate based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada	116
3.11.1.2 (I) US Carbohydrate based Intravenous Solutions Market	116
3.11.1.2 (II) Canadian Carbohydrate based Intravenous Solutions Market	116
3.11.1.3 European Carbohydrate based Intravenous Solutions Market	117
Exhibit 57. Carbohydrate based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million	117
Exhibit 58. Carbohydrate based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe	118
3.11.1.3 (I) German Carbohydrate based Intravenous Solutions Market	118
3.11.1.3 (II) French Carbohydrate based Intravenous Solutions Market	118
3.11.1.3 (III) UK Carbohydrate based Intravenous Solutions Market	118
3.11.1.3 (IV) Swiss Carbohydrate based Intravenous Solutions Market	118
3.11.1.3 (V) Russian Carbohydrate based Intravenous Solutions Market	118
3.11.1.4 Asia-Pacific Carbohydrate based Intravenous Solutions Market	119
Exhibit 59. Carbohydrate based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific  in US$ Million	119
Exhibit 60. Carbohydrate based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	120
3.11.1.4 (I) Japanese Carbohydrate based Intravenous Solutions Market	120
3.11.1.4 (II) Chinese Carbohydrate based Intravenous Solutions Market	120
3.11.1.4 (III) Indian Carbohydrate based Intravenous Solutions Market	120
3.11.1.4 (IV) Australian Carbohydrate based Intravenous Solutions Market	120
3.11.1.4 (V) South Korean Carbohydrate based Intravenous Solutions Market	120
3.11.1.5 Rest of World Carbohydrate based Intravenous Solutions Market	121
Exhibit 61. Carbohydrate based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million	121
Exhibit 62. Carbohydrate based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries	122
3.11.1.5 (II) Brazilian Carbohydrate based Intravenous Solutions Market	122
3.11.1.5 (I) Israeli Carbohydrate based Intravenous Solutions Market	122
3.11.1.5 (III) South African Carbohydrate based Intravenous Solutions Market	122
3.11.2 Salt and Electrolyte	123
3.11.2.1 Global Salt and Electrolyte based Intravenous Solutions Market	123
Exhibit 63. Salt and Electrolytes Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	124
Exhibit 64. Salt and Electrolytes Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe ,Asia-Pacific and Rest of World	125
3.11.2.2 North America Salt and Electrolyte based Intravenous Solutions Market	126
Exhibit 65. Salt and Electrolyte based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million	126
Exhibit 66. Salt and Electrolyte based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada	127
3.11.2.2 (I) US Salt and Electrolyte based Intravenous Solutions Market	127
3.11.2.2 (II) Canadian Salt and Electrolyte based Intravenous Solutions Market	127
3.11.2.3 European Salt and Electrolyte based Intravenous Solutions Market	128
Exhibit 67. Salt and Electrolyte based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and  Rest of Europe in US$ Million	128
Exhibit 68. Salt and Electrolyte based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe	129
3.11.2.3 (I) German Salt and Electrolyte based Intravenous Solutions Market	129
3.11.2.3 (II) French Salt and Electrolyte based Intravenous Solutions Market	129
3.11.2.3 (III) UK Salt and Electrolyte based Intravenous Solutions Market	129
3.11.2.3 (IV) Swiss Salt and Electrolyte based Intravenous Solutions Market	129
3.11.2.3 (V) Russian Salt and Electrolyte based Intravenous Solutions Market	129
3.11.2.4 Asia-Pacific Salt and Electrolyte based Intravenous Solutions Market	130
Exhibit 69. Salt and Electrolyte based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million	130
Exhibit 70. Salt and Electrolyte based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	131
3.11.2.4 (I) Japanese Salt and Electrolyte based Intravenous Solutions Market	131
3.11.2.4 (II) Chinese Salt and Electrolyte based Intravenous Solutions Market	131
3.11.2.4 (III) Indian Salt and Electrolyte based Intravenous Solutions Market	131
3.11.2.4 (IV) Australian Salt and Electrolyte based Intravenous Solutions Market	131
3.11.2.4 (V) South Korean Salt and Electrolyte based Intravenous Solutions Market	131
3.11.2.5 Rest of World Salt and Electrolyte based Intravenous Solutions Market	132
Exhibit 71. Salt and Electrolyte based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million	132
Exhibit 72. Salt and Electrolyte based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries	133
3.11.2.5 (II) Brazilian Salt and Electrolyte based Intravenous Solutions Market	133
3.11.2.5 (I) Israeli Salt and Electrolyte based Intravenous Solutions Market	133
3.11.2.5 (III) South African Salt and Electrolyte based Intravenous Solutions Market	133
3.11.3 Mineral and Vitamin	134
3.11.3.1 Global Mineral and Vitamin based Intravenous Solutions Market	134
Exhibit 73. Mineral and Vitamin based Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	134
Exhibit 74. Mineral and Vitamin based Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	135
3.11.3.2 North America Mineral and Vitamin based Intravenous Solutions Market	136
Exhibit 75. Mineral and Vitamin based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million	136
Exhibit 76. Mineral and Vitamin based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada	137
3.11.3.2 (I) US Mineral and Vitamin based Intravenous Solutions Market	137
3.11.3.2 (II) Canadian Mineral and Vitamin based Intravenous Solutions Market	137
3.11.3.3 European Mineral and Vitamin based Intravenous Solutions Market	138
Exhibit 77. Mineral and Vitamin based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe in US$ Million	138
Exhibit 78. Mineral and Vitamin based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe	139
3.11.3.3 (I) German Mineral and Vitamin based Intravenous Solutions Market	139
3.11.3.3 (II) French Mineral and Vitamin based Intravenous Solutions Market	139
3.11.3.3 (III) UK Mineral and Vitamin based Intravenous Solutions Market	139
3.11.3.3 (IV) Swiss Mineral and Vitamin based Intravenous Solutions Market	139
3.11.3.3 (V) Russian Mineral and Vitamin based Intravenous Solutions Market	139
3.11.3.4 Asia-Pacific Mineral and Vitamin based Intravenous Solutions Market	140
Exhibit 79. Mineral and Vitamin based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million	140
Exhibit 80. Mineral and Vitamin based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	141
3.11.3.4 (I) Japanese Mineral and Vitamin based Intravenous Solutions Market	141
3.11.3.4 (II) Chinese Mineral and Vitamin based Intravenous Solutions Market	141
3.11.3.4 (III) Indian Mineral and Vitamin based Intravenous Solutions Market	141
3.11.3.4 (IV) Australian Mineral and Vitamin based Intravenous Solutions Market	141
3.11.3.4 (V) South Korean Mineral and Vitamin based Intravenous Solutions Market	141
3.11.3.5 Rest of World Mineral and Vitamin based Intravenous Solutions Market	142
Exhibit 81. Mineral and Vitamin based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million	142
Exhibit 82. Mineral and Vitamin based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries	143
3.11.3.5 (II) Brazilian Mineral and Vitamin based Intravenous Solutions Market	143
3.11.3.5 (I) Israeli Mineral and Vitamin based Intravenous Solutions Market	143
3.11.3.5 (III) South African Mineral and Vitamin based Intravenous Solutions Market	143
3.11.4 Amino-Acid	144
3.11.4.1 Global Amino-Acid based Intravenous Solutions Market	144
Exhibit 83. Amino-Acid based Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	145
Exhibit 84. Amino-Acid based Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	146
3.11.4.2 North America Amino-Acid based Intravenous Solutions Market	147
Exhibit 85. Amino-Acid based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million	147
Exhibit 86. Amino-Acid based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada	148
3.11.4.2 (I) US Amino-Acid based Intravenous Solutions Market	148
3.11.4.2 (II) Canadian Amino-Acid based Intravenous Solutions Market	148
3.11.4.3 European Amino-Acid based Intravenous Solutions Market	149
Exhibit 87. Amino-Acid based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, UK, Switzerland, Russia and Rest of Europe in US$ Million	149
Exhibit 88. Amino-Acid based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe	150
3.11.4.3 (I) German Amino-Acid based Intravenous Solutions Market	150
3.11.4.3 (II) French Amino-Acid based Intravenous Solutions Market	150
3.11.4.3 (III) UK Amino-Acid based Intravenous Solutions Market	150
3.11.4.3 (IV) Swiss Amino-Acid based Intravenous Solutions Market	150
3.11.4.3 (V) Russian Amino-Acid based Intravenous Solutions Market	150
3.11.4.4 Asia-Pacific Amino-Acid based Intravenous Solutions Market	151
Exhibit 89. Amino-Acid based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million	151
Exhibit 90. Amino-Acid based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	152
3.11.4.4 (I) Japanese Amino-Acid based Intravenous Solutions Market	152
3.11.4.4 (II) Chinese Amino-Acid based Intravenous Solutions Market	152
3.11.4.4 (III) Indian Amino-Acid based Intravenous Solutions Market	152
3.11.4.4 (IV) Australian Amino-Acid based Intravenous Solutions Market	152
3.11.4.4 (V) South Korean Amino-Acid based Intravenous Solutions Market	152
3.11.4.5 Rest of World Amino-Acid based Intravenous Solutions Market	153
Exhibit 91. Amino-Acid based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million	153
Exhibit 92. Amino-Acid based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries	154
3.11.4.5 (II) Brazilian Amino-Acid based Intravenous Solutions Market	154
3.11.4.5 (I) Israeli Amino-Acid based Intravenous Solutions Market	154
3.11.4.5 (III) South African Amino-Acid based Intravenous Solutions Market	154
3.11.5 Other Nutrients	155
3.11.5.1 Global Other Nutrients based Intravenous Solutions Market	155
Exhibit 93. Other Nutrients based Intravenous Solutions - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	155
Exhibit 94. Other Nutrients based Intravenous Solutions - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	156
3.11.5.2 North America Other Nutrients based Intravenous Solutions Market	157
Exhibit 95. Other Nutrients based Intravenous Solutions - North American Market Estimations & Predictions (2005 - 2020) by Country for US and Canada in US$ Million	157
Exhibit 96. Other Nutrients based Intravenous Solutions - North American Market Shares (2010, 2015 & 2020) by Country for US and Canada	158
3.11.5.3 European Other Nutrients based Intravenous Solutions Market	159
Exhibit 97. Other Nutrients based Intravenous Solutions - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and  Rest of Europe in US$ Million	159
Exhibit 98. Other Nutrients based Intravenous Solutions - European Market Shares (2010, 2015 & 2020) by Country for Germany, France, United Kingdom, Switzerland, Russia and Rest of Europe	160
3.11.5.4 Asia-Pacific Other Nutrients based Intravenous Solutions Market	161
Exhibit 99. Other Nutrients based Intravenous Solutions - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific in US$ Million	161
Exhibit 100. Other Nutrients based Intravenous Solutions - Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, India, Australia, South Korea and Rest of Asia-Pacific	162
3.11.5.5 Rest of World Other Nutrients based Intravenous Solutions Market	163
Exhibit 101. Other Nutrients based Intravenous Solutions - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Israel, Brazil, South Africa and Other Countries in US$ Million	163
Exhibit 102. Other Nutrients based Intravenous Solutions - Rest of World Market Shares (2010, 2015 & 2020) by Country for Israel, Brazil, South Africa and Other Countries	164
3.12 Intravenous Solutions – Market Outlook	165
4. PRODUCT TECHNOLOGY/RESEARCH	166
4.1 Introduction	166
Intravenous Solutions	166
Composition	166
Exhibit 103. Electrolyte Requirement	166
Exhibit 104. Contents for Common Fluids (mmol/litre)	167
Application	167
Exhibit 105. Fluid Requirements in Different Clinical Situations	168
Types of Intravenous Solutions	168
Large Volume Parenterals and Small Volume Parenterals	169
Exhibit 106. Fluid Comparison	169
Intravenous versus Oral Mode of Administration	170
Risks	171
Precautions	171
Fat Emulsions	171
Dextrose	172
Plasma Expanders	172
Cyclical Parenteral Nutrition (CPN)	172
Advantages of Cyclical PN Include	173
Exhibit 107. Global Consumption of Intravenous Solutions – 2013 Estimates	173
4.2 Segmentation of Intravenous Solutions	174
Segmentation by Type	174
Partial Parenteral Nutrition	174
Total Parenteral Nutrition	174
Complications	174
Complications due to Catheter Insertion	175
Metabolic Complications	175
Segmentation by Nutrients	175
Carbohydrates	175
Carbohydrates - Source of Nutrition	175
Introduction	175
Disadvantages of Over-feeding with the Carbon Source	176
Endogenous Glucose Production and Oxidation	177
Guidelines	177
Glucose/Fat Ratio	178
Salt and Elecrtolytes	178
Salt (Sodium chloride) and/or Other Electrolytes	178
Saline	178
Concentrations	179
Minerals and Vitamins	179
Minerals and Vitamins	179
Amino Acids	179
Amino Acids and/or Protein Hydrolysates	179
Dosage of Amino Acid Solutions for Intravenous Use	180
Other	181
Fat (lipid) Emulsions	181
Plasma Extenders	181
Exhibit 108. List of Agents Administered as IV Solutions or Additives	182
PACKAGING AND IDENTIFICATION LABELING OF APIs AND INTERMEDIATES	183
Source: FDA	183
General	183
Packaging Materials	183
Label Issuance and Control	183
Packaging and Labeling Operations	184
Storage and Distribution	184
Warehousing Procedures	184
Distribution Procedures	184
Specific Guidance for Apis Manufactured by Cell Culture/Fermentation	185
General	185
Cell Culture/Fermentation	186
Harvesting, Isolation and Purification	187
Viral Removal/Inactivation steps	187
Safety Assessment of Di (2-ethylhexyl)phthalate (DEHP) Released from PVC Medical Devices	187
Safety Assessment of Di (2-ethylhexyl)phthalate (DEHP) Released from PVC Medical Devices	188
Conclusions of the Safety Assessment	188
I V Infusion of Crystalloid Fluids and Drugs	188
Total Parenteral Nutrition (TPN)	188
Parenteral Nutrition	189
Government of India - Policy and Regulations on Drugs	189
Drug Regulation and Control:	189
Maharashtra FDA: Latest Reforms	190
Procedure for Drug Application in India	191
Import and Manufacturing Licenses and Approvals:	191
Labeling Requirements	191
Drug Price Regulation	192
History of Drug Price Regulation	192
Trends in Drug Price Control – India	193
Regulations on Patent Protection	194
Finale	195
A Summary of the Chinese Pharmaceutical Market	196
Consolidating the System – The State Drug Administration	196
Pharmaceutical Regulations	198
Pricing and Reimbursement	198
Pharmaceutical Classification	199
Registration	199
Clinical Investigation	202
Legal Reform: Intellectual Property Rights	204
Conclusion	205
Law of Drug Administration – China	205
Chapter I	205
General Provisions	205
Chapter II	205
Control over Drug Manufacturers	205
Chapter III	207
Control over Drug Distributors	207
Chapter V	208
Control over Drugs	208
Chapter VI	210
Control over Drug Packaging	210
Chapter VIII	211
Inspection of Drugs	211
Chapter X	212
Supplementary Provisions	212
Application of Knowledge and Skills Framework and its Review Procedure	213
Introduction	213
Decision to Form NHS KSF	213
Purpose of Skills Framework	213
Mode of Function	213
Overview	214
Distribution of Pharmaceutical Products:	215
4.3 Intravenous Solutions – Research Briefs	216
Intravenous Food Ingredients Leading to Liver Damage, Identified	216
International Dispute Regarding Intravenous Nutrition Administration May Have Been Resolved	216
Enteral Nutrition More Effective than TPN in Severe Acute Pancreatitis	217
Survival Period Post Hospital Discharge is Not Dependent on Intravenous Drug Administration	218
Intravenous Infusion Solution Ingredients Trigger Inflammation	218
Early Nasogastric-Enteral Nutrition for Managing Severe Acute Pancreatitis	219
V. CORPORATE DIRECTORY	220
VI. PATENTS INFORMATION	231

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $4680
Multi User - US $9600
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify